CDHR1相关视网膜变性:临床表型与治疗策略
本文综述CDHR1相关常染色体隐性视网膜变性的发现与特征,该病表现为黄斑营养不良、视锥-视杆营养不良或视网膜色素变性三种表型。临床前数据显示AAV基因补充疗法在Cdhr1敲除小鼠中可带来长期形态、结构、功能和行为改善;文章还提供流程图用于与ABCA4、PRPH2、GUCY2D相关黄斑营养不良等单基因模拟病鉴别。
要点
- CDHR1相关黄斑营养不良常由既往基因检测易漏检的「沉默」核苷酸替换所致,可能诊断不足。
- 该黄斑营养不良表型与晚期干性AMD及多种单基因黄斑营养不良相似,误诊常见。
- AAV基因补充经视网膜下注射在Cdhr1敲除小鼠中恢复外段全长并延长感光细胞存活。
核心结论
- CDHR1相关视网膜变性有三种表型,AAV基因补充和CRISPR基因编辑是潜在治疗方向,临床前数据支持AAV基因补充療效。
- CDHR1相关黄斑营养不良可能诊断不足且易与晚期干性AMD及单基因模拟病混淆,准确表型与基因确认对基因治疗应用至关重要。
研究设计与样本
- 本文为综述,总结CDHR1的发现与特征、临床表型、自然史及治疗方法(包括基因补充和CRISPR基因编辑)。
- 临床前数据来自Cdhr1敲除小鼠模型的AAV基因补充治疗研究。
主要发现
- CDHR1是一种非经典钙黏蛋白,在视锥和视杆感光细胞中高表达,对功能关键的外节高级组织化必不可少。
- AAV基因补充经视网膜下注射在Cdhr1敲除小鼠中带来长期形态、结构、功能和行为改善。
- CDHR1补充恢复了疾病模型中通常缩短且排列紊乱的感光细胞外节全长,并延长感光细胞存活。
- CDHR1相关黄斑营养不良与ABCA4、PRPH2、GUCY2D相关黄斑营养不良等单基因模拟病有相似表型。
- AAV基因治疗可能对CDHR1疾病谱有益,包括与黄斑营养不良或视网膜色素变性相关的亚效变异。
关键数值与推荐
- CDHR1相关黄斑营养不良最常由一种既往基因检测被忽视的「沉默」核苷酸替换引起,可能是最常见的疾病表型。
- CDHR1编码序列可装入AAV,黄斑营养不良表型存在较大的潜在干预时间窗和较大的可治疗人群。
- 文中提供流程图用于临床区分CDHR1相关黄斑营养不良与ABCA4、PRPH2、GUCY2D相关黄斑营养不良等疾病。
临床怎么用
- 对疑似CDHR1相关视网膜变性患者应准确进行表型分析和基因确认,以支持CDHR1基因治疗的应用。
- 临床上需将CDHR1相关黄斑营养不良与晚期干性AMD及ABCA4、PRPH2、GUCY2D相关黄斑营养不良等单基因模拟病鉴别。
- 基因检测应关注既往易被忽视的「沉默」核苷酸替换,以减少CDHR1相关黄斑营养不良的漏诊。
局限性
- 本文为综述,AAV基因补充的疗效数据来自Cdhr1敲除小鼠模型,尚待临床试验验证。
- 原文未报告人体临床试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CDHR1 is a recently identified cause of autosomal recessive retinal degeneration manifesting as three distinct clinical phenotypes: macular dystrophy, cone-rod dystrophy or retinitis pigmentosa. In this review, we summarise the discovery and characterisation of CDHR1, clinical phenotypes, natural history and therapeutic approaches including gene supplementation and CRISPR gene editing. CDHR1 is a non-classical cadherin that is highly expressed in cone and rod photoreceptors and is essential for the higher-order organisation of the functionally critical outer segments. Promising pre-clinical data show that AAV gene supplementation therapy delivered by subretinal injection can lead to long-term morphological, structural, functional and behavioural improvements in the Cdhr1 knockout mouse model. Notably, CDHR1 supplementation restored full-length photoreceptor outer segments that are usually shortened and disorganised in disease models and prolonged photoreceptor survival - key mechanisms for the functional and behavioural rescue effects that were observed. The disease is likely to be underdiagnosed because CDHR1-associated macular dystrophy - likely to be the most common disease phenotype - is most often caused by a 'silent' nucleotide substitution that has previously been overlooked by genetic testing. Since the macular dystrophy phenotype has phenotypic similarities to advanced dry age-related macular degeneration (AMD), misdiagnoses are common. CDHR1-associated macular dystrophy also shares phenotypic features with a variety of monogenic masquerades such as ABCA4, PRPH2 and GUCY2D-associated macular dystrophies; we present a flowchart to guide the clinical distinction of these disorders which is now critical for patients as their treatments diverge. AAV gene therapy may be beneficial across the CDHR1 disease spectrum - including those with hypomorphic variants associated with macular dystrophy or retinitis pigmentosa. The coding sequence fits into AAV and with the macular dystrophy phenotype, there is a large time window for potential intervention and a large treatable population. Hence clinical trials are anticipated. It is therefore important that patients with CDHR1-associated retinal degeneration are accurately phenotyped and genetically confirmed to support the application of CDHR1 gene therapy.
引用
- Narayan AR, Charbel Issa P, Yusuf IH, et al. CDHR1-associated retinal degeneration: Clinical phenotypes and therapeutic approaches. Prog Retin Eye Res. 2026. PMID: 42562233. doi:10.1016/j.preteyeres.2026.101508
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。